Skip to main content
Equibles
NVCT logo

NVCT · Nuvectis Pharma, Inc.

Track NVCT — free

Use NVCT with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research NVCT.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$20.29 +0.26 (+1.30%)
Russell 2000 member Rebalance outlook locked
Market Cap
$658.80M
Shares
32.58M
Volume · Oct 7 121.1K Avg daily vol (3M) 223.66K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$20.03 Open$21.54 Day$19.79–21.54 52W close$5.65–28.53 Avg vol 30d212K Short int2.4M · 7.3% float · 14.8d Short vol62% Last earningsJun 22, 2026 DataFeb 2022–Oct 2026 Filing10-Q · Aug 4

Up next

Latest filing: 10-Q
filed Aug 4, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$27.85M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$22.16M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+9.9%
Year over year · more shares
Price change (1Y)
+231.1%
Trailing year
Short interest
7.3%
Latest settlement · 14.8 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Sell Momentum Strong Sentiment Neutral Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 15 · calm Equity put/call 0.57
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg +47%
above
Price vs 50-day avg −8%
below
RSI (14) 42
neutral
MACD trend Negative
52-week position 63%
mid-range
Momentum
relative strength
Strong
1-month return −17%
trailing
6-month return +136%
trailing
YTD return +165%
this year
Relative strength +124%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $22 › 200d $14 — 50d above 200d
Institutional flow Accumulating
+33% holders QoQ · +29 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
7.25% of float · ▲ +7.6% MoM · 14.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
84 holders — near 3-yr high, broad support
Squeeze score 70
elevated · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 85%
annualized · 1-yr
Max drawdown −37%
past year
ATR 7.8%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
2 · 3 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+47% Bullish
Price vs 50-day avg
−8% Bearish
RSI (14)
42 Neutral
MACD trend
Negative Bearish
52-week position
63% Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $22 › 200d $14 — 50d above 200d
Institutional flow Accumulating
+33% holders QoQ · +29 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
7.25% of float · ▲ +7.6% MoM · 14.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
84 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $6 Now $20 · 63% Range high $29
vs 200-day avg +47% vs 50-day avg -8%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
NVCT
Nuvectis Pharma, Inc.
this stock
$658.80M +165.3% — — 7.3%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $133.37B +10.8% +46.2% 30.7 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
 $81.13B -4.3% +20.8% 19.5 2.5%
MRNA
Moderna, Inc.
 $79.40B +535.7% +4.3% — 8.2%
CSLLY
Csl Ltd
 $61.25B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
84
% held
32.9%
Net QoQ
+6.2M sh
Top holder
TANG CAPITAL MANAGEMENT L…
Held Float
View
Held by Funds
Fund positions
76
View
Short & Settlement
Short Interest Rising
Shares short
2.4M
Days to cover
14.8d
Change
+166.3K sh
View
Short Volume
Short vol %
62%
As of
Oct 7, 2026
Short Total
View
Fails to Deliver
FTD shares
400
Value
$9.4K
As of
Aug 24, 2026
View
Off-Exchange
Off-exchange %
38.9%
Week of
Aug 31, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-26.4M
EPS diluted
$-1.32
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Sep 14, 2026
This year
15
View
Exempt Offerings
Offering
$15.9M
Filed
Aug 10, 2022
View
Earnings & Events
Webcasts
Last webcast
Sep 14, 2026
View

Performance

5D 20D 120D MTD YTD
NVCT -2.4% -16.5% +135.7% -5.2% +165.3%
SPY +2.0% +1.7% +11.3% +2.2% +14.3%
vs SPY -4.4% -18.2% +124.3% -7.3% +151.1%
Key facts CIK 1875558 CUSIP 67080T108 13F (30d) 1 filings 1 filers Visit website Investor relations